Submit Content Become a member

Recce Pharmaceuticals (ASX:RCE), which is developing a new class of synthetic anti-infectives, has successfully completed dosing of its latest cohort in its Phase I/II UTI/Urosepsis clinical trial, evaluating RECCE 327 (R327) at fast infusion rates.

An Independent Safety Committee will review and evaluate the comprehensive data from the six-subject cohort with preliminary results expected in near weeks.

Data from this trial is expected to pave the way for a Phase II UTI/Urosepsis efficacy trial, potentially establishing R327 as a frontline treatment. Administering antibiotics through rapid intravenous infusions has proven to be a safe, and effective method that significantly impacts patient treatment, reduces wait times, and alleviates nursing workloads worldwide.

"We have successfully reached a new milestone in this trial by administering a 4,000mg dose over a fast 20-minute infusion to all subjects, the highest dosage achieved so far in this clinical trial. This is a significant step forward in bringing us closer to establishing R327 as a leading treatment for those suffering from UTI/Urosepsis,” CEO James Graham said.

The full efficacious potential of R327 via intravenous administration will be made available at the completion of this clinical trial in line with study protocol.

Recce Pharmaceuticals’ synthetic anti-infectives are designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti- infectives: RECCE 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE 435 (R435) as an orally administered therapy for bacterial infections; and RECCE 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

Rate article from Colin Hay: